2C-E
4-ethyl-2,5-dimethoxyphenethylamine
Viewing r1 — Apr 21, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2C-E (2,5-dimethoxy-4-ethylphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is more cognitively demanding than 2C-B, the most familiar compound in its series. It activates serotonin receptors, disrupting the brain's normal filtering of sensory and cognitive information.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
LSD, psilocybin, mescaline +7 moreLSD, psilocybin, mescaline, DMT, 2C-B, 2C-I, 2C-D, 2C-T-2, 2C-T-7, DOM show less
Shulgin first synthesised 2C-E around 1977 and published it in PiHKAL (1991) as one of six phenethylamines he considered most significant.[2] It circulated legally as a research chemical until a 2011 mass poisoning in Minnesota — one death, ten hospitalisations — drove US scheduling.[3] It has been Schedule I in the United States since 2012,[4] controlled in most countries that have addressed it.
Subjective effects include geometric visual patterns, time alteration, enhanced introspection, ego dissolution, and intense body load. The experience is analytical and immersive — closer to mescaline in its reflective weight than to 2C-B's lighter, more sensory character. Nausea, physical tension, and pronounced bodily heaviness are characteristic unwanted effects.
2C-E does not produce physical dependence, and the lethal dose in humans is unknown — one confirmed death has been documented. The defining risk is its steep dose-response curve: a few milligrams can shift the experience from manageable to overwhelming. Human research is extremely limited — what is understood rests largely on Shulgin's original reports and community experience.[1]
History[edit]
Discovery
Alexander Shulgin first synthesised 2C-E around 1977 and documented it in PiHKAL (1991).[2] He called it "difficult and worth-while" and warned explicitly of its steep dose-response curve. He designated it one of his "magical half-dozen" — six phenethylamines he considered most significant, alongside mescaline, DOM, 2C-B, 2C-T-2, and 2C-T-7.
Key incidents and scheduling
2C-E circulated legally as a research chemical in the early 2000s. A March 2011 mass poisoning in Blaine, Minnesota — where attendees insufflated 2C-E mislabelled as 2C-I — resulted in one death and ten hospitalisations.[3][5] This drove US scheduling: 2C-E became Schedule I on 9 July 2012.[4]
Modern status
A second mass poisoning in Europe (2019) involved 2C-E combined with Bromo-DragonFly.[6] The polydrug nature makes it impossible to attribute toxicity to 2C-E alone. No clinical trial has ever been conducted; Schedule I classification has created substantial barriers to further research.
The "2C" designation refers to the two carbon atoms in the ethylamine side chain linking the aromatic ring to the terminal amine — a naming convention Shulgin applied across the entire series.[2] Among the magical half-dozen, 2C-E carries a distinctive reputation as the most cognitively demanding member of the 2C family — a compound that rewards preparation and punishes carelessness.
Chemistry[edit]
Structural class
2C-E belongs to the 2C series of substituted phenethylamines — a family defined by two methoxy groups on a benzene ring with a variable substituent at the 4-position.[2]
An ethyl group at that position distinguishes 2C-E from 2C-B (bromine) and 2C-I (iodine). Its molecular formula is C₁₂H₁₉NO₂. Forensic identification methods including gas chromatography-mass spectrometry[7] and hair-matrix testing[8] have been developed for the compound.
Pharmacology[edit]
Mechanism of action
2C-E acts as a partial agonist at serotonin receptors.[1] In the cortex, this amplifies glutamate signalling, disrupting the brain's normal filtering of sensory and cognitive input.[9][10] Its activity spans a broad range of receptor sites,[11] and it weakly inhibits serotonin and norepinephrine reuptake.[12]
Pharmacokinetics
The only human pharmacokinetic data come from ten recreational users who took 2C-E orally at doses between 6.5 and 25 mg.[1] Peak drug levels appeared approximately two hours after ingestion. Half-life, bioavailability, and volume of distribution remain unknown. Insufflated pharmacokinetics are entirely unstudied, despite insufflation being the route in the only confirmed fatality.
Metabolism
2C-E is broken down primarily by removal of methoxy groups and modification of the ethyl side chain, with metabolites processed for excretion.[13] The specific liver enzymes responsible have not been individually characterised. 2C-E is also a metabolite of the related compound 25E-NBOH.[14]
Neuroscience[edit]
Where it acts
No neuroimaging studies of 2C-E have been published. Based on its pharmacology, it is expected to reduce the brain's filtering of sensory input and increase connectivity across the cortex.[9] These are the effects — characterised for LSD and psilocybin — that produce dissolved ego boundaries, visual distortion, and heightened pattern recognition.
Theoretical context
One influential model proposes that psychedelics loosen the brain's top-down predictions, allowing sensory signals to propagate more freely — an idea that fits 2C-E's perceptual effects. The steep dose-response curve may reflect a nonlinear relationship: small increases in receptor activation could push brain activity past a tipping point.
- Does 2C-E promote neuroplasticity, and if so, at what doses relative to its psychoactive threshold?
- What drives the steep dose-response curve — receptor-level nonlinearity, network-level tipping points, or both?
- Why is the experience consistently more cognitively demanding than 2C-B, despite similar primary receptor targets?
Subjective Effects[edit]
Shulgin called 2C-E "difficult and worth-while"[2] — and the description has held. The experience is analytical and immersive, with a cognitive weight that sets it apart from most psychedelics. Visual effects are vivid, but the compound's defining character is introspective: it pushes toward depth, not lightness.
Compared to 2C-B, the most familiar compound in the series, 2C-E is consistently heavier — more cognitive, more physically taxing, less recreational. It sits closer to mescaline in its reflective depth. The steep dose-response curve means that character can shift sharply with small dose changes.
Effect Grid
At common doses (10–15 mg oral), the full psychedelic experience develops: pronounced open- and closed-eye visuals including visual drifting, tracers, after-images, colour enhancement, and emerging internal hallucinations. Time distortion becomes significant. Thought connectivity increases substantially, often producing novel conceptual associations, creativity enhancement, and pattern recognition. Emotional responses intensify — music, art, and interpersonal exchanges take on heightened significance. Synesthesia may occur.
Physically, stimulation is prominent alongside nausea (particularly during onset), muscle tension, bruxism, pupil dilation, temperature dysregulation, and increased urination. The body load is a defining feature of 2C-E at this range, distinguishing it from the lighter somatic profile of 2C-B.
The experience demands 8–12 hours of committed time. Sleep is impossible during active effects. Functional impairment is substantial — driving, operating machinery, and complex decision-making are unsafe.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Music enhancement · Symmetrical texture repetition · Tracers · Brightness alteration · Environmental patterning · After-images · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Visual diffraction · Visual morphing · Holotropic state · Auditory enhancement · Sound sensitivity · Spatial disorientation · Visual haze / noise · Visual melting · Visual acuity enhancement · Touch enhancement · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual processing acceleration · Synesthesia · Dreaming enhancement · Visual magnification · Olfactory enhancement · Tinnitus · Flashbacks · Internal hallucinations · Object transformations · External hallucinations · Visual scenery slicing · Object activation · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Brightness alteration · Environmental patterning · After-images · Depth perception distortion · Light sensitivity · Peripheral vision distortion · Perspective distortion · Visual diffraction · Visual morphing · Holotropic state · Auditory enhancement · Sound sensitivity · Spatial disorientation · Visual haze / noise · Visual melting · Visual acuity enhancement · Touch enhancement · Auditory distortion · Auditory misinterpretation · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual processing acceleration · Synesthesia · Dreaming enhancement · Visual magnification · Olfactory enhancement · Tinnitus · Flashbacks · Internal hallucinations · Object transformations · External hallucinations · Visual scenery slicing · Object activation · Visual recursion · Environmental orbism / cubism · Perspective hallucinations · Auditory hallucinations · Persisting hallucinations
Muscle tension · Stimulation · Body high · Nausea · Wakefulness · Insomnia · Physical fatigue · Restlessness · Tingling / electric sensations · Excessive sweating · Appetite suppression · Dry mouth · Heart rate perception changes · Nystagmus (eye wobbles) · Vasoconstriction · Dehydration sensation · Bodily heaviness · Bodily pressures · Body schema distortion · Breathing alteration · Dizziness · Headache · Tactile euphoria · Vibrations / buzzing · Increased urination · Bruxism · Diarrhea · Involuntary body movements · Laughter fits · Respiratory stimulation · Trembling · Sexual arousal enhancement · Abnormal heartbeat · Kundalini-like energy · Nasal congestion · Pain enhancement · Vomiting · Watery eyes · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Nausea · Wakefulness · Insomnia · Physical fatigue · Restlessness · Tingling / electric sensations · Excessive sweating · Appetite suppression · Dry mouth · Heart rate perception changes · Nystagmus (eye wobbles) · Dehydration sensation · Bodily heaviness · Bodily pressures · Body schema distortion · Breathing alteration · Dizziness · Headache · Tactile euphoria · Vibrations / buzzing · Increased urination · Bruxism · Diarrhea · Involuntary body movements · Laughter fits · Respiratory stimulation · Trembling · Sexual arousal enhancement · Abnormal heartbeat · Kundalini-like energy · Nasal congestion · Pain enhancement · Vomiting · Watery eyes · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Thought connectivity · Novelty enhancement · Aesthetic enhancement · Introspection enhancement · Openness enhancement · Thought acceleration · Cognitive flexibility · Multiple thought streams · Memory suppression · Cognitive euphoria · Cognitive fatigue · Cognitive impairment · Confusion · Increased nature relatedness · Memory fragmentation · Thought disorganization · Thought loops · Creativity enhancement · Analysis enhancement · Cognitive dysphoria · Focus suppression · Humor enhancement · Information processing suppression · Synchronicity · Information processing enhancement · Language enhancement · Language suppression · Memory replays · Motivation suppression · Focus enhancement · Motivation enhancement · Amnesia
Introspection enhancement · Openness enhancement · Thought acceleration · Cognitive flexibility · Multiple thought streams · Memory suppression · Cognitive euphoria · Cognitive fatigue · Cognitive impairment · Confusion · Increased nature relatedness · Memory fragmentation · Thought disorganization · Thought loops · Creativity enhancement · Analysis enhancement · Cognitive dysphoria · Focus suppression · Humor enhancement · Information processing suppression · Synchronicity · Information processing enhancement · Language enhancement · Language suppression · Memory replays · Motivation suppression · Focus enhancement · Motivation enhancement
Euphoria · Catharsis · Simultaneous emotions · Dysphoria · Irritability · Empathy enhancement · Anhedonia
Irritability · Empathy enhancement · Anhedonia
Disinhibition · Sociability suppression · Social connection · Social disconnection · Flow state · Communication enhancement · Sociability enhancement · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Flow state · Communication enhancement · Sociability enhancement · Boundary dissolution · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Entity contact · Non-dual awareness · Cessation · Death-rebirth sequence · Transpersonal memory access · Voidness
Transpersonal memory access · Voidness
Mindfulness enhancement · Recursive awareness
Timeline
First alerts appear 20–45 minutes after ingestion: a subtle shift in visual texture, mild stomach awareness, and a growing sense that something has changed. The onset is slower than 2C-B.
Effects build steadily over 30–60 minutes. Nausea is most prominent during this phase. Colours brighten, visual drifting begins, and body stimulation increases.
Maximum intensity sustained for 2–3 hours, centred around the 2-hour saliva Tmax. Full visual phenomena, time distortion, thought connectivity, and emotional amplification. Body load peaks here — muscle tension, temperature dysregulation, and cardiovascular stimulation are most pronounced.
Effects sustain at a diminished but still significant level for 1. 5–3 hours. Visuals and cognitive effects remain active but less overwhelming.
A gradual return toward baseline over 1. 5–3 hours. Residual visual enhancement and thought patterns persist but functional capacity returns.
Residual mood elevation, enhanced colour perception, and reflective thinking persist for 6–12 hours. Mild physical fatigue is common. Sleep quality may be reduced even after subjective effects resolve.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute toxicity
No lethal dose data exist for 2C-E in any species. One confirmed human death is documented: a 19-year-old died of cardiac arrest in March 2011 after insufflating 2C-E at a party in Minnesota.[3] Ten others were hospitalised with delirium, paranoia, and dangerously high body temperature.[5]
A second mass poisoning in Europe (2019) combined 2C-E with Bromo-DragonFly.[6] The polydrug nature makes it impossible to attribute toxicity to 2C-E alone.
Clinical presentation
2C-drug poisoning typically produces hallucinations, agitation, elevated blood pressure, rapid heart rate, seizures, and dangerously high body temperature.[15] Severe cases can progress to muscle breakdown, cardiovascular collapse, and metabolic crisis.[16]
The presentation can resemble either a stimulant overdose or excess serotonin activity, reflecting 2C-E's dual receptor activation and mild reuptake inhibitor.[1][15]
Heart and circulation
In the only controlled human observation (ten participants, oral doses 6.5–25 mg), elevated blood pressure and heart rate were documented, with no serious adverse events.[1]
Treatment of 2C-E poisoning is primarily supportive. Benzodiazepines are first-line for agitation and seizure control. Active cooling is critical for dangerously high body temperature. No specific antidote exists.[15]
Psychological Risks
The steep dose-response curve amplifies psychological risk. Shulgin explicitly warned that a few milligrams can separate a manageable experience from a very frightening one.[2] Survivors of the 2011 Minnesota incident reported paranoia, auditory distortions, and delirium.[5]
No substance-specific data on persistent perceptual changes (HPPD) or psychosis following 2C-E use have been published. The prolonged duration (8–12 hours) increases the cumulative burden of difficult experiences. People with personal or family history of psychosis or bipolar disorder face elevated risk from any serotonergic psychedelic.
Tolerance & Dependence
2C-E produces rapid tolerance through downregulation of serotonin receptors in the frontal cortex.[17] Tolerance typically builds within days and subsides within several days of abstinence. It cross-tolerates with other classical psychedelics — LSD, psilocybin, mescaline, DMT, and other 2C compounds.[17]
2C-E is not habit-forming. No cases of physical dependence, withdrawal, or compulsive use have been reported.
Drug Interactions
The main interaction risk comes from 2C-E's serotonin activity — activating serotonin receptors while mildly blocking serotonin reuptake.[1]
Tramadol is classified as dangerous. Tramadol blocks serotonin reuptake[18] and is linked to serotonin syndrome — a life-threatening overheating and seizure response — when combined with other serotonergic agents.[19] Combined with 2C-E, this risk is substantially elevated.[18]
MAOIs block the breakdown of serotonin. Combined with 2C-E's receptor activation and mild reuptake inhibition, this creates significant serotonin syndrome risk. inferred
SSRIs and SNRIs may blunt psychedelic effects with chronic use. Acute co-administration could increase serotonin toxicity risk. inferred
Lithium has been associated with seizures when combined with psychedelics; the mechanism is unclear. inferred
Stimulants (amphetamines, cocaine) carry additive cardiovascular strain risk. inferred
Bromo-DragonFly was documented in a mass poisoning combined with 2C-E;[6] the specific mechanism of combined toxicity is uncharacterised.
Cannabis may potentiate psychedelic effects or increase psychological distress; no 2C-E-specific data exist.
Contraindications
No contraindications specific to 2C-E have been established. The following are inferred from its pharmacological class:
Psychotic disorders and bipolar disorder — personal or family history is an absolute contraindication. 2C-E risks psychosis or psychiatric destabilisation in these individuals. inferred
Heart conditions — 2C-E raises blood pressure and heart rate.[1] High blood pressure, irregular heart rhythm, or structural heart disease increases risk. inferred
Seizure disorders — seizures are a documented feature of 2C-class poisoning,[15] suggesting 2C-E may lower the seizure threshold. inferred
Concurrent serotonergic medications — MAOIs, tramadol, SSRIs, and SNRIs are contraindicated due to serotonin syndrome risk.
Pregnancy and breastfeeding — no safety data exist. inferred
Harm Reduction[edit]
Forms & Identification
The steep dose-response curve makes precise dosing more consequential than with most psychedelics. A difference of 2–3 mg can shift the experience from manageable to overwhelming. Volumetric dosing — dissolving a known quantity in a measured volume of liquid — is strongly preferred over weighing individual doses on consumer scales.
Reagent testing confirms phenethylamine presence but cannot distinguish between individual 2C-series members. The 2011 Minnesota fatality occurred because 2C-E was mislabelled as 2C-I[5] — reagent kits would not have caught this substitution. Quantitative analysis (FTIR or laboratory testing services) is the only reliable method for positive identification.
Guidelines
- Test every batch. Reagent testing confirms phenethylamine presence but cannot distinguish 2C-E from other 2C compounds. Quantitative analysis is preferred when available.
- Use a milligram-precision scale and consider volumetric dosing for greater accuracy.
- Start low. First-time users should begin at the lower end of the common dose range and wait the full onset period (30–90 minutes oral) before considering any redose.
- Do not insufflate. Insufflation dramatically compresses onset, amplifies peak intensity, and increases body load. The only confirmed fatality involved this route. Insufflated pharmacokinetics are entirely uncharacterised.
- Clear the schedule. The experience lasts 8–12 hours, and residual effects may persist beyond that. Do not plan to drive, work, or meet obligations.
- Eat lightly 2–3 hours before ingestion. An empty stomach intensifies nausea; a full stomach may delay onset and lead to impatient redosing.
- Stay hydrated but avoid excessive water intake.
- Prepare for body load. Have blankets, comfortable seating, and temperature control available. Heat packs or a warm bath can ease physical tension.
Set & Setting
2C-E's cognitive depth and prolonged duration demand more preparation than lighter psychedelics. A familiar, comfortable environment with minimal external demands is essential. The compound is poorly suited to social or public settings at moderate-to-high doses, where cognitive load can become isolating.
An experienced, sober sitter is strongly recommended for anyone unfamiliar with the compound or working above an established dose range. The sitter should understand the expected duration, the possibility of intense body load and psychological difficulty, and the importance of calm reassurance over active intervention.
Aftercare & integration. The cognitive intensity of a 2C-E experience often benefits from deliberate processing afterward. Journaling within the first 24–48 hours — while impressions are still accessible — can help consolidate insights and identify themes worth revisiting.
Allow at least one full day of rest. Sleep may be disrupted the first night; this typically normalises within 24 hours. Eat well, hydrate, and avoid stimulants or other psychoactive substances for several days.
If the experience was difficult, talking with a trusted person or an integration-trained therapist can help contextualise distressing material. Persistent anxiety, depersonalisation, or intrusive imagery lasting more than two weeks warrants professional support.
Recovery & Support
2C-E does not produce physical dependence, and compulsive use patterns are rare due to rapid tolerance. If psychedelic use has become a way of avoiding difficult emotions or responsibilities, or if experiences are causing lasting distress, support is available.
- Fireside Project (62-FIRESIDE / 623-473-7433) — psychedelic peer support line
- MAPS Integration List — directory of therapists experienced with psychedelic integration
- SAMHSA National Helpline (1-800-662-4357) — free, confidential referral service
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency
Most 2C-E experiences involve discomfort that resolves without intervention. Seek immediate help if any of the following occur:
- Seizure or convulsions
- Chest pain or irregular heartbeat
- Body temperature that feels dangerously hot through clothing
- Loss of consciousness or unresponsiveness
- Severe confusion with inability to recognise surroundings or people
- Self-harm behaviour or complete disconnection from reality
Immediate steps
- 1. Call emergency services if any of the above signs are present.
- 2. Move the person to a quiet, cool space.
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear).
- 4. If overheating, apply cool water to skin, fan the person, and remove excess clothing.
- 5. Do not restrain a person in delirium unless they pose immediate physical danger to themselves or others.
- 6. Do not induce vomiting.
What to tell the dispatcher
State that the person took a synthetic psychedelic (2C-E), the approximate amount and time of ingestion, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Medical management
No specific antidote exists for 2C-E. Hospital treatment is supportive: benzodiazepines for agitation and seizures, active cooling for dangerously high body temperature.[15]
Legal Status[edit]
2C-E is controlled as a prohibited substance in most jurisdictions that have specifically addressed it. In the United States, it was placed in Schedule I under the synthetic Drug Abuse Prevention Act of 2012.[4] The United Kingdom classified it as Class A under a phenethylamine catch-all provision as early as 2002.[20]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I | Scheduled 9 July 2012 under SDAPA; DEA drug codes established 4 January 2013[4] |
| United Kingdom | Class A | Controlled since 2002 under phenethylamine catch-all amendment to Misuse of Drugs Act 1971[20] |
| Sweden | Controlled | Scheduled 1 October 2004[20] |
| Denmark | Schedule I | Scheduled 8 April 2007[20] |
| Israel | Controlled | Scheduled December 2007[20] |
| China | Category I psychotropic | Scheduled September 2010[20] |
| Germany | Anlage I (BtMG) | Scheduled 13 December 2014[20] |
| Brazil | Controlled | Scheduled 18 February 2014[20] |
| Finland | Banned | Scheduled 19 December 2014[20] |
| Japan | Designated substance | Under designated substances law; specific date unconfirmed[20] |
| New Zealand | Schedule 3 / Class C | Controlled under analogues provision[20] |
| Canada | Unconfirmed (possibly Schedule III) | Erowid notes potential Schedule III status but marks as unconfirmed[20] |
| Australia | Likely Schedule 9 (unconfirmed) | By analogy with other 2C compounds; not independently verifiedcitation needed |
Legal status varies by jurisdiction and changes frequently. This information may be out of date. Nothing here constitutes legal advice.
references
- [1]
- [2]
- [3]
- [4] ^abcdDEA (2013) Establishment of drug codes for 26 substances. Final rule — Federal Register PMID:23289157
- [5]
- [6] ^abcIwersen-Bergmann S, Lehmann S, Heinemann A, Schröder C, Müller A, Jungen H, Andresen-Streichert H, Pueschel K, Vidal C, Mercer-Chalmers-Bender K (2019) Mass poisoning with NPS: 2C-E and Bromo-DragonFly — International Journal of Legal Medicine doi:10.1007/s00414-018-1882-9